The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. ⋯ Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).